A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 176

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1034
Function: getPubMedXML

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3152
Function: GetPubMedArticleOutput_2016

File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

Dosing strategies for once-daily extended release tacrolimus in kidney transplant recipients based on genotype. | LitMetric

Background: Tacrolimus extended-release tablets have been Food and Drug Administration-approved for use in the kidney transplant population. Dosing requi rements often vary for tacrolimus based on several factors including variation in metabolism based on expression. Patients who express often require higher dosing of immediate-release tacrolimus, but this has not been established for tacrolimus extended-release tablets in the setting.

Aim: To obtain target trough concentrations of extended-release tacrolimus in kidney transplant recipients according to genotype.

Methods: Single-arm, prospective, single-center, open-label, observational study (ClinicalTrials.gov: NCT037 13645). Life cycle pharma tacrolimus (LCPT) orally once daily at a starting dose of 0.13 mg/kg/day based on actual body weight. If weight is more than 120% of ideal body weight, an adjusted body weight was used. LCPT dose was adjusted to maintain tacrolimus trough concentrations of 8-10 ng/mL. Pharmacogenetic analysis of genotype was performed at study conclusion.

Results: Mean time to therapeutic tacrolimus trough concentration was longer in intermediate and extensive metabolizers non-expressers (6 d 13.5 d 4.5 d; = 0.025). Mean tacrolimus doses and weight-based doses to achieve therapeutic concentration were higher in intermediate and extensive metabolizers non-expressers (16 mg 16 mg 12 mg; = 0.010) (0.20 mg/kg 0.19 mg/kg 0.13 mg/kg; = 0.018). extensive metabolizers experienced lower mean tacrolimus trough concentrations throughout the study period compared to intermediate metabolizers and non-expressers (7.98 ng/mL 9.18 ng/mL 10.78 ng/mL; = 0 0.008). No differences were identified with regards to kidney graft function at 30-d post-transplant. Serious adverse events were reported for 13 (36%) patients.

Conclusion: Expression of leads to higher starting doses and incremental dosage titration of extended-release tacro limus to achieve target trough concentrations. We suggest a higher starting dose of 0.2 mg/kg/d for expressers.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758687PMC
http://dx.doi.org/10.5500/wjt.v13.i6.368DOI Listing

Publication Analysis

Top Keywords

trough concentrations
16
kidney transplant
12
body weight
12
tacrolimus trough
12
extensive metabolizers
12
metabolizers non-expressers
12
tacrolimus
11
tacrolimus kidney
8
transplant recipients
8
tacrolimus extended-release
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!